RUNX3 and neoplasm: On the other hand, miR-130b has been shown to be highly expressed in CD133+ tumor-initiating cells in HCC [59] and to directly target the well-known tumor suppressor RUNX3, suggesting the prominent oncogenic role of miR-130b in hepatocarcinogenesis [60].